CAMBRIDGE, Mass.--(BUSINESS WIRE)--C4 Therapeutics today announced the appointment of Thomas E. Needham, Jr., MBA, to the position of Chief Business Officer. Mr. Needham joins with over 20 years of experience in venture capital, business development, corporate strategy and executive management responsibilities in public and private biotechnology companies. In this new role, Mr. Needham will lead C4 Therapeutics’ corporate and business development, finance, legal and corporate communications functions.
“Mr. Needham has a wealth of industry and business development experience with a proven track record of driving growth and executing on strategic partnership and R&D collaborations,” said Jason Fisherman, M.D., President and Chief Executive Officer of C4. “We anticipate that his contributions will accelerate the growth of the Company and support our mission to develop a new class of medicines using our Degronimid™ platform.”
“There is a unique opportunity at C4 Therapeutics to build an innovative pipeline and grow a business around a new class of targeted protein degradation (TPD) therapeutics which leverage the human body’s natural ubiquitin/proteasome clearance mechanism,” said Mr. Needham. “I look forward to utilizing my experience in corporate strategy and business development to drive the execution of key growth strategies, including pharmaceutical corporate partnerships and the expansion of our own proprietary pipeline to translate Degronimid™ science into groundbreaking new medicines for patients.”
Prior to joining C4, Mr. Needham was Managing Director at Synthesis Capital, where he was involved in the management of two healthcare venture funds focused on investments in biotechnology, pharmaceuticals and medical technology. Previously, he was Principal at Advent International, a global private equity firm, as a member of the healthcare venture capital deal team. Prior to this, he held Vice President of Business Development positions at GPC Biotech and Mitotix, Inc., where he led the negotiation and closing of a number of strategic transactions, including negotiation of industry partnerships with global pharmaceutical companies, R&D collaborations, licensing and M&A transactions.
Mr. Needham received a B.A. in history and economics from Bowdoin College and an MBA in marketing and finance from Babson College - Franklin W. Olin Graduate School of Business.
About C4 Therapeutics
C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs.
More information about C4 Therapeutics is available at www.C4Therapeutics.com.
